first_imgApr 4, 2005 (CIDRAP News) – Sanofi Pasteur has won a $97 million federal contract to develop cell-culture technology for making influenza vaccines and to design a facility to use this technology to make a pandemic flu vaccine, federal officials have announced.Flu vaccines are currently grown in chicken eggs, a process that takes at least 6 months. Several companies have been experimenting with ways to grow vaccines in mammalian or other cells, in the hope of speeding up the process. The chance that H5N1 avian flu could lead to a human flu pandemic has stimulated these efforts.In the Apr 1 contract announcement by the Department of Health and Human Services (HHS), HHS Secretary Mike Leavitt said, “This action begins the process of speeding up influenza vaccine production, improving surge capacity and scaling up U.S. manufacturing capability.”Under the 5-year contract, Sanofi Pasteur (formerly Aventis Pasteur) will develop inactivated flu vaccines using human cells and manufacture enough doses for clinical trials, the HHS statement said. Sanofi was the main supplier of inactivated flu vaccine for the US market in the 2004-05 flu season.”In addition, Sanofi Pasteur will develop plans for a U.S. manufacturing facility capable of producing at least 300 million doses of a pandemic influenza vaccine using this technology,” HHS said.The statement said it takes nearly 9 months to make currently licensed flu vaccines. After health agencies select the three viral strains they think will be most common in the coming flu season, the strains must be adapted to grow in eggs. The adapted virus strains are injected separately into millions of fertilized eggs, which are then incubated. Finally the viruses are harvested from the eggs, killed, and blended into a vaccine that includes all three strains.HHS cited several advantages of using cell-culture technology to make flu vaccines. Viruses don’t need to be adapted to grow in eggs, and manufacturers can freeze cells in advance and then thaw and grow them in large volumes in the event of a shortage or pandemic. Also, the method is safe from certain risks associated with egg-based production, such as the chance of eggs being contaminated by various poultry diseases. Finally, cell-based vaccines could be used by people who can’t receive the currently licensed vaccines because they are allergic to eggs.The HHS announcement didn’t suggest how fast it would be possible to produce vaccines with cell-culture technology or how soon Sanofi might have a vaccine ready for clinical trials. HHS officials could not be reached in time to provide more information for this report.According to a Washington Post report published last November, officials at several companies that are developing cell-based flu vaccine technology said the production process would take about 5 months, shortening the conventional process by about a month.In November 2004 HHS awarded a contract to Sanofi Pasteur to ensure a year-round supply of eggs for flu vaccine production. The government also has awarded contracts in the past year to develop and test a human flu vaccine based on the H5N1 avian flu virus.See also:Apr 1 HHS announcement 9, 2004, HHS announcement of contract to provide egg supplies for flu vaccine production read more

first_imgWould you like to read more?Register for free to finish this article.Sign up now for the following benefits:Four FREE articles of your choice per monthBreaking news, comment and analysis from industry experts as it happensChoose from our portfolio of email newsletters To access this article REGISTER NOWWould you like print copies, app and digital replica access too? SUBSCRIBE for as little as £5 per week.last_img

first_imgPreviously BCA corporate secretary Raymon Yonarto said the acquisition of Rabobank Indonesia aimed to support Indonesia’s banking architecture.“It is also meant to support our subsidiaries’ existing businesses,” he said in a statement to the IDX last year.The bank would also study the possibility of merging Rabobank with a BCA subsidiary in the future, according to the statement.Rabobank’s acquisition will be the second recent acquisition by BCA. In November 2019, BCA took complete ownership of Bank Royal for Rp 988.05 billion (US$67.24 million).Rabobank Indonesia announced earlier last year that it would stop operations in June 2020. President director Jos Luhukay said the decision was made to align with the global business strategy of the Rabobank Group, which would focus on the supply chain of food and agricultural products.Topics : Publicly listed Bank Central Asia (BCA) expects to complete its acquisition of agriculture-focused Rabobank Indonesia by the end of the third quarter of this year, having received approval from shareholders.BCA shareholders gave their consent to the bank’s plan to acquire Rabobank’s 3.72 million shares during an extraordinary general meeting on July 30.The shares represent full ownership of the company, which is currently owned by Dutch bank Cooperative Rabobank UA, PT Aditirta Suryasentosa, PT Antarindo Optima, PT Antariksabuana Citranagara and PT Mitra Usaha Kencana Sejati. “The total value of this acquisition will refer to a fixed premium of US$20.5 million plus a one-time adjusted book value on closing in September 2020,” BCA said in a statement.After getting the approval of its shareholders, BCA said it would submit applications to the Financial Services Authority (OJK) to get the body’s approval for the acquisition. The process is expected to be complete by the end of the third quarter of this year.BCA stocks, traded on the Indonesia Stock Exchange (IDX) under the symbol BBCA, had dropped 1.52 percent as of 11:04 Jakarta time on Monday as the exchange’s main gauge, the Jakarta Composite Index (JCI), plunged 2.75 percent.Foreign investors dumped, on net, Rp 135.8 billion worth of BCA stocks during Monday morning trading as the local stock market was hit by negative sentiments because of contractions announced by big economies such as the United States, France and Germany, last week. The bourse as a whole recorded a foreign net sell of over Rp 878 billion.last_img read more

first_img Press Association Wrong Turn makes a quick reappearance after winning at Killarney last weekend in the Kilfeacle Stud ‘Portrait Gallery’ Handicap Chase. Ruby Walsh will be in the plate as Tony Martin’s charge tries to defy a penalty. Ballyreesode has a 9lb rise to contend with in the Arkenvale Ltd Handicap Hurdle, with Rolling Rocket and Marshim, as well as Sterling Stuff, primed to exploit any weakness. The latter’s trainer Robert Tyner saddles two in the Glenview And Rathberry Stud Novice Hunters Chase, with Soaring High and Bingo Bash both boasting solid credentials between the flags. However, Ibetellingyoualie and She’s Got Grit have previous experience of jumping obstacles under Rules and that could prove to be crucial. Willie Mullins and Gigginstown House Stud team up with impressive Loughnamore winner Unic De Bersy in the (C&G) Point-To-Point INH Flat Race. There are also a couple of point-to-point winners in the mares’ version, with Our Belief, Scamaill Liath, Fennis Moll and Teresa Lisbon possibly the pick of the bunch. Sizing Rio is the star of the show at Tipperary on Thursday as he makes his fencing debut in the Kedrah House Stud ‘Well Chosen’ Beginners Chase.center_img Henry de Bromhead pulled his charge out of the race won by Felix Yonger at Punchestown last Saturday and has settled on what appears to be a slightly easier task here. Sizing Rio could well be completing a double for De Bromhead if he wins as the trainer also has a prime contender for the opening Healy Partners Architects Maiden Hurdle in Turica. last_img read more